# BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

> **NCT01832922** · PHASE1 · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01832922
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-04-27
- **Final completion:** 2016-11-28
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01832922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01832922, "BR in Patients With CLL With Comorbidities and/or Renal Dysfunction". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01832922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*